Guidelines for Infection Control in the Urological Field, including Urinary Tract Management (revised second edition)
The Committee for the Development of Guidelines for Infection Control in the Urological Field, including Urinary Tract Management of the Japanese Urological Association, together with its systematic review team and external reviewers, have prepared a set of practice guidelines, an abridged version of which is published herein. These guidelines cover the following topics: (i) foundations of infection control, standard precautions, route-specific precautions, and occupational infection control (including vaccines); (ii) the relationship between urologists and infection control; (iii) infection control in urological wards and...
Source: Current Awareness Service for Health (CASH) - October 15, 2021 Category: Consumer Health News Source Type: news

Africa: Africa CDC Welcomes Historic Go-Ahead for Malaria Vaccine
[African Union] The African continent is making headway in the fight against malaria among young children. Being at the forefront in establishing, strengthening, and supporting member states in disease control and surveillance for priority diseases including HIV and AIDs, tuberculosis, malaria, COIVD-19, hepatitis, and non-communicable diseases in the region, the African Union (AU) through the Africa Centres for Disease Control and Prevention (Africa CDC) has welcomed the World Health Organization's (WHO) historic go-ahea (Source: AllAfrica News: Malaria)
Source: AllAfrica News: Malaria - October 11, 2021 Category: Infectious Diseases Source Type: news

YouTube bans all anti-vaccine misinformation
The new policy expands the rules to misleading claims about long-approved vaccines, such as those against measles and hepatitis B, as well as to falsehoods about vaccines in general. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - September 30, 2021 Category: Health Management Authors: Davey Alba Source Type: news

YouTube bans all anti-vaccine misinformation
The new policy expands the rules to misleading claims about long-approved vaccines, such as those against measles and hepatitis B, as well as to falsehoods about vaccines in general. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 30, 2021 Category: Biotechnology Authors: Davey Alba Source Type: news

YouTube Bans Anti-Vaccine Misinformation
The new set of policies will cover not just the Covid-19 vaccines or long-approved vaccines against diseases like measles and hepatitis B, but also general claims about vaccines, YouTube said. (Source: NYT Health)
Source: NYT Health - September 29, 2021 Category: Consumer Health News Authors: Davey Alba Tags: YouTube.com Vaccination and Immunization Rumors and Misinformation Coronavirus (2019-nCoV) Kennedy, Robert F Jr Mercola, Joseph M (1954- ) Children ' s Health Defense Social Media Source Type: news

NIAID Scientists Find a Key to Hepatitis C Entry into Cells
Understanding Structure of HCV Proteins Could Aid in Vaccine Development. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - September 21, 2021 Category: American Health Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Africa: Messenger RNA - How It Works in Nature and in Making Vaccines
[The Conversation Africa] Vaccines have long been an integral part of public health programmes around the world, reducing the spread and severity of infectious diseases. The success of immunisation strategies to protect children from diseases like polio, hepatitis B, and measles, and adults from influenza and pneumococcal disease, can be seen globally. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 7, 2021 Category: African Health Source Type: news

Estimating cost effectiveness of hepatitis B vaccination in US adults
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2021 Category: Drugs & Pharmacology Source Type: news

Fauci:'Good Idea' to Implement School Vaccine Mandates Fauci:'Good Idea' to Implement School Vaccine Mandates
"We've done this for decades and decades, requiring polio, measles, mumps, rubella, hepatitis," he added."So this would not be something new, requiring vaccinations for children to come to school."WebMD Health News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - August 30, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Vaccine Access Negotiations to Resume as New Variants Spread
Vaccine access negotiations are at critical juncture. While many countries support the intellectual property rights waiver, including the European parliament the European Union does not. Credit: PAHO/Karen GonzálezBy Lyndal RowlandsMelbourne, Australia , Aug 30 2021 (IPS) A committee that has spent almost a year negotiating the terms of a temporary intellectual property waiver for Covid-19 medicines will reconvene in September after pausing for the European Summer. As new variants spread rapidly around the world, the deadlock in the World Trade Organization Trade-Related Aspects of Intellectual Property Rights (TRI...
Source: IPS Inter Press Service - Health - August 30, 2021 Category: International Medicine & Public Health Authors: Lyndal Rowlands Tags: COVID-19 Development & Aid Economy & Trade Featured Global Headlines Health Humanitarian Emergencies TerraViva United Nations COVAX COVID-19 vaccines TRIPS. WTO Source Type: news

Progress Toward Hepatitis B Control - World Health Organization European Region, 2016-2019
This report describes progress toward hepatitis B control in the World Health Organization European Region. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - July 29, 2021 Category: American Health Tags: Hepatitis B Hepatitis B Vaccination MMWR Morbidity & Mortality Weekly Report Source Type: news

Cameroon: 13th World Hepatitis Day - Free Screening Ongoing in Yaounde
[Cameroon Tribune] The exercise, taking place at the International Vaccination Centre ends on Friday, July 30, 2021. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 28, 2021 Category: African Health Source Type: news

Vaccine sales help GSK beat forecasts
Demand for jabs for meningitis, diphtheria and hepatitis recovers after pandemic disruption (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 28, 2021 Category: Pharmaceuticals Source Type: news

CDC: Advisory Committee on Immunization Practices (ACIP)
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is hosting a virtual meeting on September 29-30, 2021. The agenda will include discussions on cholera vaccine, hepatitis vaccines, herpes zoster vaccines, orthopoxvirus vaccine, pneumococcal vaccine, and tickborne encephalitis vaccine. Includes information on how to submit public comments or request permission to make a public comment during the meeting. Registration is not required and the meeting is open to the public, available online via a live webcast. (Source: Federal Register updates via the Rural Assistance Center)
Source: Federal Register updates via the Rural Assistance Center - July 26, 2021 Category: Rural Health Source Type: news

European Duplicity Undermines Anti-Pandemic Efforts
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Jul 20 2021 (IPS) Despite facing the world’s worst pandemic of the last century, rich countries in the World Trade Organization (WTO) have blocked efforts to enable more affordable access to the means to fight the pandemic. Everyone knows access for all to the means for testing, treatment and prevention – including diagnostic tests, therapeutic medicines, personal protective equipment and vaccines – is crucial. Anis ChowdhuryEuropean deceit In October 2020, South Africa and India requested the WTO to temporarily suspend relevant provisions...
Source: IPS Inter Press Service - Health - July 20, 2021 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Aid Development & Aid Economy & Trade Global Headlines Health Human Rights Humanitarian Emergencies TerraViva United Nations Jomo Kwame Sundaram & Anis Chowdhury Source Type: news

New COVID-19 vaccine candidate provides effective option for low- to mid-income countries
(Emory Health Sciences) Combining yeast-expression technology and a novel adjuvant formulation to produce a COVID-19 vaccine candidate is effective against SARS-COV-2 and promises to be easy to produce at large scale and cost-effective, important aspects for vaccinating people worldwide, especially in low- to middle-income countries. Results from the study, which applied lessons learned from the hepatitis b vaccine platform technology, are published online today in Science Immunology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2021 Category: International Medicine & Public Health Source Type: news

Hepatitis C vaccine could be rolled out within five years, says Nobel Prize winner who discovered virus
(European Society of Clinical Microbiology and Infectious Diseases) A vaccine to protect against infection with hepatitis C could be in use within 5 years, says Professor Sir Michael Houghton, who won the Nobel Prize for Medicine and Physiology along with three other scientists for discovering the hepatitis C virus (HCV) in 1989. Sir Michael will discuss the development of a vaccine in a special presentation at this year's European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 11, 2021 Category: International Medicine & Public Health Source Type: news

Introducing birth-dose hepatitis  B vaccination would be cost effective in Burkina Faso
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news

Hepatitis A Virus Infections Among Men Who Have Sex with Men - Eight U.S. States, 2017-2018
This report describes trends in hepatitis A cases among men who have sex with men. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - June 17, 2021 Category: American Health Tags: Diseases & Conditions Healthy Living Hepatitis A Hepatitis A Vaccination Infection MMWR Morbidity Mortality Weekly Report Outbreaks Sexual Health Source Type: news

A third dose of COVID-19 vaccine increased antibody levels in organ transplant recipients with a sub
(American College of Physicians) A case series published in Annals of Internal Medicine found that a third dose of vaccine increased antibody levels in organ transplant recipients who had suboptimal response to standard vaccination. These findings suggest that clinical trials are warranted to determine whether booster doses should be incorporated into clinical practice for transplant patients, just as they have been for hepatitis B and influenza vaccinations. This is the first study to report on response to a third vaccine dose. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 14, 2021 Category: Infectious Diseases Source Type: news

Two-dose hepatitis B vaccine cost effective versus 3-dose vaccine
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Teens Ages 12 to 15 Should Get Pfizer-BioNTech ’s COVID-19 Vaccine, Says a CDC Expert Panel
Following the US Food and Drug Administration’s decision on May 10 to extend emergency use authorization for the Pfizer-BioNTech vaccine to include 12- to 15-year olds, the Centers for Disease Control added its recommendation that teens in that age group should be vaccinated with the shot. The expert panel of the CDC’s Advisory Committee on Immunization Practices makes immunization recommendations, and determined that based on the evidence from a study of more than 2200 teens conducted by Pfizer-BioNTech, that the vaccine was safe and effective. During the day-long meeting, however, the members discussed whethe...
Source: TIME: Health - May 13, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Hepatitis C drugs multiply effect of COVID-19 antiviral Remdesivir
When combined with drugs currently used to treat hepatitis C, the antiviral remdesivir is 10 times more effective in treating cells infected with SARS-CoV-2, the virus that causes COVID-19. Published this week in Cell Reports, this finding - from Gaetano Montelione, a professor of chemistry and chemical biology at Rensselaer Polytechnic Institute, and his collaborators at the Icahn School of Medicine at Mount Sinai and the University of Texas at Austin - raises the potential for repurposing available drugs as COVID-19 antivirals in cases where a vaccine isn't practical or effective. (Source: World Pharma News)
Source: World Pharma News - April 27, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How DaVita is working to directly administer Covid-19 vaccines to patients across the country
The Denver-based kidney care company is using the processes it developed for flu and Hepatitis B vaccines and applying them to Covid-19. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 30, 2021 Category: American Health Authors: Jensen Werley Source Type: news

How DaVita is working to directly administer Covid-19 vaccines to patients across the country
The Denver-based kidney care company is using the processes it developed for flu and Hepatitis B vaccines and applying them to Covid-19. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 30, 2021 Category: Biotechnology Authors: Jensen Werley Source Type: news

End Vaccine Apartheid Before Millions More Die
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Mar 23 2021 (IPS) At least 85 poor countries will not have significant access to coronavirus vaccines before 2023. Unfortunately, a year’s delay will cause an estimated 2.5 million avoidable deaths in low and lower-middle income countries. As the World Health Organization (WHO) Director-General has put it, the world is at the brink of a catastrophic moral failure. Anis Chowdhury Vaccine apartheid The EU, US, UK, Switzerland, Canada and their allies continue to block the developing country proposal to temporarily suspend the World Trade Organization (W...
Source: IPS Inter Press Service - Health - March 23, 2021 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Development & Aid Economy & Trade Featured Global Headlines Health Human Rights Humanitarian Emergencies TerraViva United Nations Source Type: news

ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have madeunprecedented progress in advancing treatments and vaccines to help fight COVID-19. At this time, three vaccines and several treatments have received emergency use authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) with one treatment receiving FDA approval. Additional candidates under investigation have also shown promise. (Source: The Catalyst)
Source: The Catalyst - March 8, 2021 Category: Pharmaceuticals Tags: Vaccines Coronavirus Source Type: news

U.S. Will Have Enough COVID-19 Vaccines for All Adults by End of May, Biden Says
(WASHINGTON) — President Joe Biden said Tuesday that the U.S. expects to take delivery of enough coronavirus vaccines for all adult Americans by the end of May, two months earlier than anticipated, as his administration announced that drugmaker Merck & Co. will help produce rival Johnson & Johnson’s newly approved shot. With the bolstered supply, Biden also announced he would be using the powers of the federal government to direct all states to prioritize vaccinating teachers, and said the federal government would provide the doses directly through its pharmacy program. He challenged states to administe...
Source: TIME: Health - March 2, 2021 Category: Consumer Health News Authors: ZEKE MILLER, LINDA A. JOHNSON and JONATHAN LEMIRE/AP Tags: Uncategorized COVID-19 wire Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo a...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holde...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Science - January 11, 2021 Category: Science Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot
This article originally appeared on Akron Beacon Journal: Majority of Summit EMS workers opt out of COVID-19 vaccine ___ (c)2021 the Akron Beacon Journal (Akron, Ohio) Visit the Akron Beacon Journal (Akron, Ohio) at www.ohio.com Distributed by Tribune Content Agency, LLC. The post Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot appeared first on JEMS. (Source: JEMS Special Topics)
Source: JEMS Special Topics - January 7, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus News News Feed EMS EMT Ohio Paramedic Source Type: news

Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot
This article originally appeared on Akron Beacon Journal: Majority of Summit EMS workers opt out of COVID-19 vaccine ___ (c)2021 the Akron Beacon Journal (Akron, Ohio) Visit the Akron Beacon Journal (Akron, Ohio) at www.ohio.com Distributed by Tribune Content Agency, LLC. The post Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot appeared first on JEMS. (Source: JEMS Operations)
Source: JEMS Operations - January 7, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus News News Feed EMS EMT Ohio Paramedic Source Type: news

Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot
This article originally appeared on Akron Beacon Journal: Majority of Summit EMS workers opt out of COVID-19 vaccine ___ (c)2021 the Akron Beacon Journal (Akron, Ohio) Visit the Akron Beacon Journal (Akron, Ohio) at www.ohio.com Distributed by Tribune Content Agency, LLC. The post Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot appeared first on JEMS. (Source: JEMS: Journal of Emergency Medical Services News)
Source: JEMS: Journal of Emergency Medical Services News - January 7, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus News News Feed EMS EMT Ohio Paramedic Source Type: news

Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot
This article originally appeared on Akron Beacon Journal: Majority of Summit EMS workers opt out of COVID-19 vaccine ___ (c)2021 the Akron Beacon Journal (Akron, Ohio) Visit the Akron Beacon Journal (Akron, Ohio) at www.ohio.com Distributed by Tribune Content Agency, LLC. The post Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot appeared first on JEMS. (Source: JEMS Latest News)
Source: JEMS Latest News - January 7, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus News News Feed EMS EMT Ohio Paramedic Source Type: news

Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot
This article originally appeared on Akron Beacon Journal: Majority of Summit EMS workers opt out of COVID-19 vaccine ___ (c)2021 the Akron Beacon Journal (Akron, Ohio) Visit the Akron Beacon Journal (Akron, Ohio) at www.ohio.com Distributed by Tribune Content Agency, LLC. The post Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot appeared first on JEMS. (Source: JEMS Administration and Leadership)
Source: JEMS Administration and Leadership - January 7, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus News News Feed EMS EMT Ohio Paramedic Source Type: news

Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot
This article originally appeared on Akron Beacon Journal: Majority of Summit EMS workers opt out of COVID-19 vaccine ___ (c)2021 the Akron Beacon Journal (Akron, Ohio) Visit the Akron Beacon Journal (Akron, Ohio) at www.ohio.com Distributed by Tribune Content Agency, LLC. The post Majority of Summit (OH) EMS Workers Opt Out of COVID-19 Shot appeared first on JEMS. (Source: JEMS Patient Care)
Source: JEMS Patient Care - January 7, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus News News Feed EMS EMT Ohio Paramedic Source Type: news

Don ’t Let the Pandemic Stop Your Shots
Even as older adults await the coronavirus vaccine, many are skipping the standard ones. That ’s not wise, health experts say. (Source: NYT Health)
Source: NYT Health - December 28, 2020 Category: Consumer Health News Authors: Paula Span Tags: your-feed-science Whooping Cough Shingles (Disease) Diphtheria Coronavirus (2019-nCoV) Influenza Elderly Epidemics Drugs (Pharmaceuticals) Pneumonia your-feed-healthcare Vaccination and Immunization Hepatitis Tetanus Minorities Source Type: news

The Ambulance Science Podcast: Make Up Your Own Mind About the Vaccine
Get every episode of The Ambulance Science Podcast by subscribing to Apple Podcasts or Google Podcasts. Where I’m coming from (compared to most of my colleagues): Master’s in Public Health with a concentration in Health Policy from Yale Medical School.FT Faculty at GWU School of Medicine & Southern Connecticut State University MPH Program, and long-time adjunct faculty at NYMC MPH program in Health Policy.Assistant Commissioner of Health at the NYC Department of Health & Mental Hygiene during the first SARS outbreak.Served as State EMS Director, Consultant to Public Health ...
Source: JEMS Special Topics - December 14, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Podcasts Ambulance Science Source Type: news

NIDCR's Winter 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Winter 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Welcomes New Director Rena D’Souza Rena N. D’Souza, DDS, MS, PhD, was sworn in as the director of NIDCR by NIH Director Francis S. Collins, MD, PhD, on October 13. Prior to joining NIH, Dr. D’Souza was the assistant vice president for academic affairs and education for health s...
Source: NIDCR Science News - December 4, 2020 Category: Dentistry Source Type: news

Health and care heroes honoured in parliamentary awards
Doctors and nurses working to combat Hepatitis C in the homeless during the pandemic, the team behind the UK ’s first virtual reality lung rehabilitation programme launched this year and the research team working on the COVID-19 vaccine have all been recognised in the regional round of the NHS parliamentary awards. (Source: NHS Networks)
Source: NHS Networks - November 24, 2020 Category: UK Health Source Type: news

New video: See how strong IP protections lead to stronger treatments for patients
Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. A strong IP system is what has allowed the American biopharmaceutical industry to become the world leader in new medicine development and has allowed us to make unprecedented strides in treating everything from acute leukemia to hepatitis C and more. (Source: The Catalyst)
Source: The Catalyst - November 9, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Intellectual Property IP Explained Source Type: news

A promising discovery could lead to better treatment for Hepatitis C
(Institut national de la recherche scientifique - INRS) Virologists at Institut national de la recherche scientifique (INRS) have identified a critical role played by a cellular protein in the progression of Hepatitis C virus infection, paving the way for more effective treatment. No vaccine currently exists for Hepatitis C virus infection, which affects more than 130 million people worldwide and nearly 250,000 Canadians. Antivirals exist but are expensive and not readily available in developing countries, where the disease is most prevalent. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 22, 2020 Category: Infectious Diseases Source Type: news

3 Win Nobel Medicine Prize for Discovering Hepatitis C Virus
(STOCKHOLM) — Americans Harvey J. Alter and Charles M. Rice and British-born scientist Michael Houghton won the Nobel Prize for medicine on Monday for their discovery of the hepatitis C virus, a major source of liver disease that affects millions worldwide. Announcing the prize in Stockholm, the Nobel Committee noted that the trio’s work identified a major source of blood-borne hepatitis that couldn’t be explained by the previously discovered hepatitis A and B viruses. Their work, dating back to the 1970s and 1980s, has helped saved millions of lives, the committee said. “Thanks to their discovery, ...
Source: TIME: Science - October 5, 2020 Category: Science Authors: DAVID KEYTON and FRANK JORDANS / AP Tags: Uncategorized News News Desk wire Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news